Skip to main content
SpringerLink
Log in

Leprosy

Recognition and Treatment

  • Therapy in Practice
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Leprosy is a slowly progressive, chronic infectious disease caused by the bacillus Mycobacterium leprae. It is a very serious, mutilating and stigmatizing disease in many parts of the world and early diagnosis and therapy is the most important strategy for its control. The skin and peripheral nerves are the most affected organs. It is highly infective, but has low pathogenicity and low virulence with a long incubation period. The geographical distribution of leprosy has varied greatly with time and it is now endemic only in tropical and subtropical regions such as India and Brazil.

The diagnosis of leprosy is made from the clinical picture, but must be complimented by skin bacilloscopy and histopathology. Leprosy has a number of distinct clinical presentations. Indeterminate leprosy is frequently the initial form consisting of a few lesions that either evolves into the other forms or resolves spontaneously. Lepromatous leprosy is the more contagious form and affects mainly the skin. In addition, some peripheral nerves may be thickened and other symptoms maybe present. The tuberculid form affects the skin and nerves, although usually there are few lesions. There is also a form borderline between the lepromatous and tuberculoid forms.

Current treatment of leprosy involves use of 3 drugs: rifampicin (rifampin); clofazimine; and dapsone. Multidrug therapy aims to effectively eliminate M. leprae in the shortest possible time to prevent resistance from occurring. The duration of therapy was recently reduced from 24 to 12 months. Other treatment options are under evaluation in both preclinical and clinical trials and a number show promise. The combination of rifampicin, ofloxacin and minocycline given as a single dose has been recommended for the treatment of paucibacillar leprosy.

Only when physicians, other health workers, and the population in endemic countries become fully aware of, and able to recognize, the disease in its initial phase, will it be possible for therapy to be instituted at the very beginning with either the standard scheme or the newer ones. Intervention at such an early stage will avoid the onset of the more serious signs and symptoms, meaning that leprosy will eventually become a less important public health problem. Therefore, efforts must be made to alert populations at risk and all health workers of the importance of an early diagnosis and treatment in leprosy infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 9
Fig. 10
Table II
Table III

Similar content being viewed by others

References

  1. World Health Organization A guide to leprosy control. 2nd ed. Geneva: WHO 1988: 6–8

    Google Scholar 

  2. Canizares O., Harman R., Adriaans B. Leprosy. In: Canizares O., Harman R., editors. Clinical tropical dermatology. 2nd ed. Boston: Blackwell Scientific, 1992: 165–200

    Google Scholar 

  3. Dorland’s illustrated medical dictionary. 28th ed. Philadelphia: Saunders, 1994: 732

  4. Sampaio S.A.P., Rivitti E.A., editors. Dermatologia. 2nd ed. Säo Paulo: Artes Médicas, 1998: 467–470

    Google Scholar 

  5. Azulay R.D., Azulay D.R. Dermatologia. 2nd ed. Rio de Janeiro: Guanabara Koogan, 1997: 174–189

    Google Scholar 

  6. Lockwood D.N.J., Bryceson A.D.M. Leprosy. In: Champion R.H., Burton J.L., Burns D.A., et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. 6th ed. Oxford: Blackwell Science, 1998: 1215–1235

    Google Scholar 

  7. Klatser P., van Beers S., Madjib B., et al. Detection of Mycobacterium leprae nasal carriers in populations for which leprosy is endemic. J Clin Microbiol 1993; 31: 2947–2951

    PubMed  CAS  Google Scholar 

  8. Dorland’s illustrated medical dictionary. 28th ed. Philadelphia: Saunders, 1994: 915

  9. Bhatia A., Katoch K., Narayanan R., et al. Clinical and histopathological correlation in the classification of leprosy. Int J Lepr 1993; 61: 433–438

    CAS  Google Scholar 

  10. Miller R.A. Leprosy (Hansen’s disease). In: Wilson J.D., Braunwald E., Isselbacher K.J., et al., editors. Harrison’s principles of internal medicine. 12th ed. New York: McGraw-Hill, 1991: 645–648

    Google Scholar 

  11. World Health Organization Weekly Epidemiological Record Geneva: WHO; 2 October 1998: 308–312

    Google Scholar 

  12. Williams D., Gillis T., Fiallo P., et al. Detection of Mycobacterium leprae and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR. Mol Cell Probes 1992; 6: 401–410

    Article  PubMed  CAS  Google Scholar 

  13. World Health Organization A guide to eliminating leprosy as public health problem. Geneva: WHO, 1995: 15–16

    Google Scholar 

  14. World Health Organization A guide to leprosy control. 2nd ed. Geneva: World Health Organization, 1988: 27–28

    Google Scholar 

  15. Ridley D.S., Jopling W.H. Classification of leprosy according to immunity — a five-group system. Int J Lepr Other Mycobact Dis 1966; 34: 255–273

    PubMed  CAS  Google Scholar 

  16. World Health Organization 7th WHO Expert Committee on leprosy. Geneva: WHO, 26 May–3 June, 1997

    Google Scholar 

  17. Ramos-e-Silva M., Carneiro S.C.S. Vasculitis in Latin America. Clin Dermatol 1999; 17: 663–670

    Article  PubMed  CAS  Google Scholar 

  18. Fleury R.N., Ura S., Opromolla D.V.A. Fenômeno de Lucio (eritema necrosante). Hansen Int 1995; 20: 60–65

    Google Scholar 

  19. Ramos-e-Silva M., Fernandes N.C. Parasitic diseases including tropical diseases. In: Parish L.C., Brenner S., Ramos-e-Silva M., editors. Women’s dermatology. London: Parthenon, 2001: 291–302

    Google Scholar 

  20. Cestari T.F. Hanseníase e gestaçao. In: Talhari S., Neves R.G., editors. Hanseníase. 3rd ed. Manaus: Grafica e Editora Tropical, 1997: 83–86

    Google Scholar 

  21. Scollard D.M., Smith T., Bhoopat L., et al. Epidemiologic characteristics of leprosy reaction. Int J Lepr 1994; 62: 559–567

    CAS  Google Scholar 

  22. Le Grand A. Women and leprosy. A review. Lepr Rev 1997; 68: 203–211

    PubMed  Google Scholar 

  23. Souza C.S., Figueiredo F., Foss N.T. Fenômeno de Lúcio e pentoxifilina. Hansen Int 1997; 22: 125

    Google Scholar 

  24. Mshana R.N., Belehu A., Stoner G.L., et al. Demonstration of mycobacterial antigens in leprosy tissues. Int J Lepr 1982; 50: 1–9

    CAS  Google Scholar 

  25. Ridley M.J., Russell D.F., Ridley D.S. Imunoperoxidase study of immunological factors in skin lesions across the spectrum of leprosy. Int J Lepr 1982; 50: 11–19

    CAS  Google Scholar 

  26. Williams D.L., Gillis T.P., Booth R.J., et al. The use of specific DNA probe and PCR for detection of M. leprae. J Infect Dis 1990; 162: 193–200

    Article  PubMed  CAS  Google Scholar 

  27. Cho S.N., Cellona R.V., Fajardo Jr T.T., et al. Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. Int J Lepr Other Mycobact Dis 1991; 59: 25–31

    PubMed  CAS  Google Scholar 

  28. Faget G.H., Johansen F.A., Ross H. Sulfanilamide in the treatment of leprosy. Public Health Rep 1942; 57: 1892–1899

    Article  Google Scholar 

  29. Oliveira M.L.W. A cura da hanseníase x magnitude das recidivas. An bras Dermatol 1997; 72: 63–69

    Google Scholar 

  30. Ramos-e-Silva J. A chimiotherapia da lepra; seu estado actual. An Bras Dermatol 1926; 2: 17–28

    Google Scholar 

  31. Grosset J. Traitement antibactérien. In: Sansarricq H., editor. La Lèpre. Paris: Ellipses 1995: 226–244

    Google Scholar 

  32. Jain S., Sehgal V. Multidrug therapeutic challenges in leprosy. Int J Dermatol 1997; 36: 493–496

    Article  PubMed  CAS  Google Scholar 

  33. Opromolla D.V.A. Terapêutica da hanseníase. Medicina 1997; 30: 345–350

    Google Scholar 

  34. Browne S.G. B663; possible anti-inflammatory action in lepromatous leprosy. Lepr Rev 1965; 36: 9–11

    PubMed  CAS  Google Scholar 

  35. Rees R.J.W., Pearson J.M.H., Waters M.F.R. Experimental and clinical studies on rifampicin in the treatment of leprosy. BMJ 1970; 1: 89–92

    Article  PubMed  CAS  Google Scholar 

  36. World Health Organization Expert Committee on leprosy. 5th report. Geneva: WHO, Technical report series 1977; 51

    Google Scholar 

  37. WHO Technical Report Series. Geneva: WHO, Technical report series 675; 1982

  38. WHO/LEP Action Programme for the elimination of leprosy. Status Report. Updated. Geneva: WHO, 1997: 10–11

    Google Scholar 

  39. Ji B., Perani E., Petinon C., et al. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. Int J Lepr 1992; 60: 556–561

    CAS  Google Scholar 

  40. Levy L., Shepard C.C., Fasal P. The bactericidal effect of rifampicin on M. leprae in man: a) singles doses of 600, 900 and 1200mg; and b) daily doses of 300mg. Int J Lepr 1976; 44: 183–187

    CAS  Google Scholar 

  41. WHO/The Leprosy Unit Risk of relapses in leprosy. Indian J Lepr 1995; 67: 13–26

    Google Scholar 

  42. Gelber R.H. Activity of minocycline in Mycobacterium leprae-infected mice. J Infect Dis 1987; 156: 236–239

    Article  PubMed  CAS  Google Scholar 

  43. Franzblau S.G., Hastings R.C. In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother 1988; 32: 1758–1762

    Article  PubMed  CAS  Google Scholar 

  44. Grosset J.H., Ji B., Guelpa-Lauras C.C., et al. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr 1988; 56: 259–264

    CAS  Google Scholar 

  45. Grosset J.H., Ji B., Guelpa-Lauras C.C., et al. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr 1990; 58: 281–295

    CAS  Google Scholar 

  46. WHO/APEL Action programme for the elimination of leprosy Efficacy of a singledose multidrug therapy for the treatment of single lesion paucibacillary leprosy. Indian J Lepr 1997; 69: 121–129

    Google Scholar 

  47. Katoch V.M. Is there a microbiological rationale for single-dose treatment of leprosy? Lepr Rev 1998; 69: 2–5

    PubMed  CAS  Google Scholar 

  48. Prasad K.N. Single dose multidrug therapy for single lesion paucibacillary leprosy. Indian J Lepr 1998; 70: 215–216

    PubMed  CAS  Google Scholar 

  49. Salafia A. Single dose multidrug therapy for single lesion paucibacillary leprosy. Indian J Lepr 1998; 70: 216–218

    PubMed  CAS  Google Scholar 

  50. Ganapati R., Revankar C.R., Pai V.V., et al. Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up. Int J Lepr 1999; 67: 308–309

    CAS  Google Scholar 

  51. Revankar C.R., Pai V.V., Samy M.S., et al. Single-dose treatment for paucibacillary leprosy; field implications. Int J Lepr 1999; 67: 312–313

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sector of Dermatology, School of Medicine, HUCFF-UFRJ, Universidade Federal do Rio de Janeiro, Rua Sorocaba 464/205, 22271-110, State of Rio de Janeiro, Brazil

    Marcia Ramos-e-Silva

  2. Sector of Dermatology, Alfredo da Matta Foundation, Manaus, State of Amazonas, Brazil

    Paula Frassinetti Bessa Rebello

Authors
  1. Marcia Ramos-e-Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paula Frassinetti Bessa Rebello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcia Ramos-e-Silva.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramos-e-Silva, M., Rebello, P.F.B. Leprosy. Am J Clin Dermatol 2, 203–211 (2001). https://doi.org/10.2165/00128071-200102040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200102040-00001

Keywords

Search

Navigation